In this Feb. 26, 2019 file photo, Albert Bourla, chief executive officer of Pfizer, prepares to testify before the Senate Finance Committee hearing on drug prices, on Capitol Hill in Washington. Pfizer Inc.'s CEO says it can't seek emergency authorization of its COVID-19 vaccine before the third week of November — and that's if everything goes well. The announcement on Friday, Oct. 16, 2020, by Bourla reflects estimates from leading scientists that its unlikely data would start to emerge until November or December showing any of the leading vaccine candidates work. (AP Photo/Pablo Martinez Monsivais, File)
Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday.
Despite President Donald Trump’s repeated promises of a vaccine before Election Day, scientists have been cautioning that it’s unlikely data showing a leading shot actually works would come until November or December.
Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.
Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. But in Friday’s announcement, he made clear that effectiveness is only part of the equation.
The vaccine also must be proven safe. And to qualify for an “emergency use authorization,” any COVID-19 vaccine must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects are likely to appear.
Bourla estimated Pfizer's 44,000-person study will reach that milestone in the third week of November.
“We are operating at the speed of science,” he wrote in a letter posted to the company’s website.
The vaccine made by Pfizer and its German partner BioNTech is among several leading candidates in final testing.
Even if a vaccine emerges by year’s end, only limited doses will be available right away. The U.S. government is deciding who would be first in line, almost certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Kellie Romack, Chief Digital Innovation Officer at ServiceNow, reveals the company’s latest announcement and how it’s shaping the future of work and tech.
Raina Moskowitz, CEO of The Knot Worldwide, unpacks the 2025 Global Wedding Report, from Gen Z trends to how Taylor Swift's wedding could reshape the industry.
Nestlé has dismissed its CEO Laurent Freixe after an investigation into an undisclosed relationship with a direct subordinate. The company announced on Monday that the dismissal was effective immediately. An investigation found that Freixe violated Nestlé’s code of conduct. He had been CEO for a year. Philipp Navratil, a longtime Nestlé executive, will replace him. Chairman Paul Bulcke stated that the decision was necessary to uphold the company’s values and governance. Navratil began his career with Nestlé in 2001 and has held various roles, including CEO of Nestlé's Nespresso division since 2024.
Kraft Heinz is splitting into two companies a decade after they joined in a massive merger that created one of the biggest food companies on the planet. One of the companies will include brands such as Heinz, Philadelphia cream cheese and Kraft Mac & Cheese. The other will include brands like Oscar Mayer, Kraft Singles and Lunchables. When the company formed in 2015 it wanted to capitalize on its massive scale, but shifting tastes complicated those plans, with households seeking to introduce healthier options at the table. Kraft Heinz's net revenue has fallen every year since 2020.